Diabetes is ‘facet’ of long COVID syndrome
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Individuals with COVID-19 had increased risk and burden for diabetes and use of diabetes drugs at least 30 days after infection compared with people without COVID-19. Researchers evaluated data of 181,280 participants with a positive COVID-19 test between March 2020 and September 2021 who survived the first 30 days of infection. They compared those data with data from the same database on individuals with no evidence of COVID-19: 4,118,441 participants as contemporary controls enrolled between March 2020 and September 2021, and 4,286,911 participants as historical controls enrolled between March 2018 and September 2019.

All participants were without diabetes prior to study enrollment and were followed for a median of 352 days. Researchers estimated post-acute COVID-19 risks for incident diabetes, use of diabetes medications and a composite of both outcomes.

Compared with the contemporary control group, participants with COVID-19 had an increased risk for incident diabetes (HR = 1.4; 95% CI, 1.36-1.44) as well as excess burden of incident diabetes (13.46 per 1,000 people; 95% CI, 12.11-14.84) at 12 months. In addition, participants with COVID-19 had an increased risk for incident use of diabetes drugs (HR = 1.85; 95% CI, 1.78-1.92) and excess burden of use (12.35 per 1,000 people; 95% CI, 11.36-13.38).

Researchers also observed an increased risk for a composite endpoint of incident diabetes or diabetes drug use (HR = 1.46; 95% CI, 1.43-1.5) as well as an excess burden of the composite of both outcomes (18.03 per 1,000 people; 95% CI, 16.59-19.51) at 12 months. When participants were categorized according to severity of the acute phase of COVID-19 infection — not hospitalized, hospitalized or admitted to the ICU — risks and burdens increased with severity.

Source: https://www.healio.com/news/endocrinology/20220331/diabetes-is-facet-of-long-covid-syndrome